

[Dexamethasone](#)

Essential medicine status

Section:

[17. Gastrointestinal medicines](#) [17.2. Antiemetic medicines](#)

ATC codes: [H02AB02](#)

EMLc

Indication

Nausea or vomiting ICD11 code: [MG10](#)

INN

Dexamethasone

Medicine type

Chemical agent

List type

Core

Formulations

Oral > Liquid: 0.5 mg per 5 mL (as sodium phosphate) ; 2 mg per 5 mL (as sodium phosphate)

Parenteral > General injections > unspecified: 4 mg per mL in 1 mL ampoule dexamethasone phosphate (as sodium phosphate, equivalent to 3.3 mg/mL dexamethasone base)

Oral > Solid > tablet: 0.5 mg (as dexamethasone base) ; 0.75 mg (as dexamethasone base) ; 1.5 mg (as dexamethasone base) ; 4 mg (as dexamethasone base) ; 2 mg (as dexamethasone base)

EML status history

First added in 2009 ([TRS 958](#))

Changed in 2025 ([TRS 1064](#))

Sex

All

Age

Also recommended for children

Therapeutic alternatives

The recommendation is for this specific medicine

Patent information

Patents have expired in most jurisdictions

Read more [about patents](#).

Wikipedia

[Dexamethasone](#)

DrugBank

[Dexamethasone](#)

Summary of evidence and Expert Committee recommendations



Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended: - to modify the listings to reflect the amount of dexamethasone in terms of dexamethasone salt or dexamethasone base.